Gossypol+Phenformin - Haim Bio
Alternative Names: NYH817100; NYH817G+NYH100P; NYH817G-NYH100P; StarvanipLatest Information Update: 28 Mar 2024
At a glance
- Originator National Cancer Center (Korea); Yonsei University Health System
- Class Antineoplastics; Biguanides; Sesquiterpenes
- Mechanism of Action Aldehyde dehydrogenase inhibitors; Apoptosis stimulants; Cholestenone 5 alpha-reductase inhibitors; Electron transport complex I inhibitors; Growth inhibitors; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Haematological-malignancies in South Korea (PO)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in South Korea (PO)
- 12 Mar 2020 Chemical structure information added